Cargando…

Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies

Detalles Bibliográficos
Autores principales:	Hu, Jie, Peng, Pai, Wang, Kai, Fang, Liang, Luo, Fei-yang, Jin, Ai-shun, Liu, Bei-zhong, Tang, Ni, Huang, Ai-long
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905196/ https://www.ncbi.nlm.nih.gov/pubmed/33633321 http://dx.doi.org/10.1038/s41423-021-00648-1

Ejemplares similares

Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera
por: Hu, Jie, et al.
Publicado: (2021)

Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody
por: Yue, Shuai, et al.
Publicado: (2021)

Changes in the humoral immunity response in SARS-CoV-2 convalescent patients over 8 months
por: Peng, Pai, et al.
Publicado: (2021)

Significantly reduced abilities to cross-neutralize SARS-CoV-2 variants by sera from convalescent COVID-19 patients infected by Delta or early strains
por: Pan, Ting, et al.
Publicado: (2021)

Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern
por: Dupont, Liane, et al.
Publicado: (2021)

Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum
por: Uriu, Keiya, et al.
Publicado: (2021)

Impact of mAb-induced A475V substitution on viral fitness and antibody neutralization of SARS-CoV-2 omicron variants in the presence of monoclonal antibodies and human convalescent sera
por: Viriyakitkosol, Ratchanont, et al.
Publicado: (2023)

Sensitivity of SARS-CoV-2 antibody tests with late convalescent sera
por: Kannenberg, Judith, et al.
Publicado: (2021)

SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons
por: Rössler, Annika, et al.
Publicado: (2022)

Cross-neutralization of SARS-CoV-2 Kappa and Delta variants by inactivated vaccine-elicited serum and monoclonal antibodies
por: Cheng, Lin, et al.
Publicado: (2021)

Neutralization heterogeneity of circulating SARS-CoV-2 variants to sera elicited by a vaccinee or convalescent
por: Zhang, Meng, et al.
Publicado: (2022)

Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
por: Wang, Xun, et al.
Publicado: (2022)

Increased immune escape of the new SARS-CoV-2 variant of concern Omicron
por: Hu, Jie, et al.
Publicado: (2022)

Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests
por: Chan, Kwok-Hung, et al.
Publicado: (2013)

Differential efficiencies to neutralize the novel mutants B.1.1.7 and 501Y.V2 by collected sera from convalescent COVID-19 patients and RBD nanoparticle-vaccinated rhesus macaques
por: Li, Rong, et al.
Publicado: (2021)

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
por: Supasa, Piyada, et al.
Publicado: (2021)

SARS CoV-2 Delta variant exhibits enhanced infectivity and a minor decrease in neutralization sensitivity to convalescent or post-vaccination sera
por: Kuzmina, Alona, et al.
Publicado: (2021)

Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes
por: Tada, Takuya, et al.
Publicado: (2021)

NEUTRALIZATION TESTS WITH SERA OF CONVALESCENT OR IMMUNIZED ANIMALS AND THE VIRUSES OF SWINE AND HUMAN INFLUENZA
por: Francis, Thomas, et al.
Publicado: (1936)

Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination
por: Yu, Xiaoqi, et al.
Publicado: (2022)

Neutralizing antibodies in convalescent patients
por: Uhl, Lion F. K., et al.
Publicado: (2020)

SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera
por: Kuzmina, Alona, et al.
Publicado: (2021)

Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents
por: Ma, Chengbao, et al.
Publicado: (2022)

Different Neutralization Sensitivity of SARS-CoV-2 Cell-to-Cell and Cell-Free Modes of Infection to Convalescent Sera
por: Kruglova, Natalia, et al.
Publicado: (2021)

SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster
por: Lusvarghi, Sabrina, et al.
Publicado: (2021)

Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera
por: Tada, Takuya, et al.
Publicado: (2021)

High Heterogeneity of Virus-Neutralizing and RBD-Binding Activities of COVID-19 Convalescent Sera
por: Astakhova, E. A., et al.
Publicado: (2022)

SARS corona virus peptides recognized by antibodies in the sera of convalescent cases
por: Guo, Jian-Ping, et al.
Publicado: (2004)

Correction: Changes in the humoral immunity response in SARS-CoV-2 convalescent patients over 8 months
por: Peng, Pai, et al.
Publicado: (2022)

Humoral responses in naive or SARS-CoV-2 experienced individuals vaccinated with an inactivated vaccine
por: Peng, Pai, et al.
Publicado: (2021)

Cross-Neutralization of SARS-CoV-2-Specific Antibodies in Convalescent and Immunized Human Sera against the Bat and Pangolin Coronaviruses
por: Srisutthisamphan, Kanjana, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 BQ.1.1, CH.1.1, and XBB.1.5 by breakthrough infection sera from previous and recent waves in China
por: Wang, Xun, et al.
Publicado: (2023)

A spike protein S2 antibody efficiently neutralizes the Omicron variant
por: Hu, Jia, et al.
Publicado: (2022)

Evaluation of cross-neutralizing antibodies in children infected with omicron sub-variants
por: Peng, Weiyu, et al.
Publicado: (2023)

Convalescents
Publicado: (1907)

Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies
por: Yamasoba, Daichi, et al.
Publicado: (2022)

Absence of neutralizing antibodies against the Omicron SARS-CoV-2 variant in convalescent sera from individuals infected with the ancestral SARS-CoV-2 virus or its Gamma variant
por: Villas-Boas, Lucy Santos, et al.
Publicado: (2022)

Antigenic Fingerprinting of H5N1 Avian Influenza Using Convalescent Sera and Monoclonal Antibodies Reveals Potential Vaccine and Diagnostic Targets
por: Khurana, Surender, et al.
Publicado: (2009)

Limits of Monoclonal Antibody Treatment in Pregnant Women Complicated with COVID-19 Due to The Omicron Variant
por: Cha, Hyun-Hwa, et al.
Publicado: (2022)

Intraperitoneal Injection of Anti-Sera
por: King, H. H.
Publicado: (1924)

Cannot write session to /tmp/vufind_sessions/sess_7m52lm5tr9j0gsiod1dgr5ed3n